Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

被引：0
作者：
Jagannath, Sundar [1 ]
Vij, Ravi [2 ]
Stewart, A. Keith [3 ]
Somlo, George [4 ]
Jakubowiak, Andrzej [5 ]
Reiman, Tony [6 ]
Trudel, Suzanne [7 ]
Taylor, Jessica [8 ]
Fuhrman, Diana [8 ]
Cruickshank, Scott [8 ]
Schwartz, Richard [8 ]
Kunkel, Lori [8 ]
Siegel, David [9 ]
机构：
[1] St Vincents Comp Canc Ctr, New York, NY USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Mayo Clin, Scottsdale, AZ USA
[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[5] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[6] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[8] Proteolix Inc, Clin Operat, San Francisco, CA USA
[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[10] MMRC, Norwalk, CT USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [11] LONG-TERM FOLLOW-UP IN PX-171-003-A1, AN OPEN-LABEL, SINGLE-ARM PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM): ANALYSIS BY SUBGROUPS OF INTEREST
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Kukreti, V.
    Alsina, M.
    Somlo, G.
    Kunkel, L.
    Wong, A.
    Orlowski, R. Z.
    Stewart, A. K.
    Singhal, S.
    Jagannath, S.
    ANNALS OF ONCOLOGY, 2011, 22 : 200 - 200
  • [12] An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    Vij, Ravi
    Wang, Michael
    Kaufman, Jonathan L.
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Stewart, A. Keith
    Kukreti, Vishal
    Jagannath, Sundar
    McDonagh, Kevin T.
    Alsina, Melissa
    Bahlis, Nizar J.
    Reu, Frederic J.
    Gabrail, Nashat Y.
    Belch, Andrew
    Matous, Jeffrey V.
    Lee, Peter
    Rosen, Peter
    Sebag, Michael
    Vesole, David H.
    Kunkel, Lori A.
    Wear, Sandra M.
    Wong, Alvin F.
    Orlowski, Robert Z.
    Siegel, David S.
    BLOOD, 2012, 119 (24) : 5661 - 5670
  • [13] PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
    Siegel, David
    Wang, Luhua
    Orlowski, Robert Z.
    Kaufman, Jonathan L.
    Stewart, A. Keith
    Kukreti, Vishal
    Alsina, Melissa
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    McDonagh, Kevin T.
    Belch, Andrew
    Bahlis, Nizar J.
    Shustik, Chaim
    Le, Mai H.
    Kunkel, Lori
    Bennett, Mark K.
    Kauffman, Michael
    Vij, Ravi
    BLOOD, 2009, 114 (22) : 128 - 128
  • [14] RESULTS OF PX-171-004, AN ONGOING OPEN-LABEL, PHASE II STUDY OF CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (R/R MM) WITH OR WITHOUT PRIOR BORTEZOMIB EXPOSURE
    Stewart, K.
    Siegel, D.
    Wang, M.
    Kaufman, J.
    Jakubowiak, A.
    Jagannath, S.
    Kukreti, V.
    McDonagh, K.
    Alsina, M.
    Bahlis, N.
    Belch, A.
    Gabrail, N.
    Le, M.
    Bennett, M.
    Vij, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 452 - 452
  • [15] A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)
    Berdeja, Jesus
    Savona, Michael
    Mace, Joseph R.
    Hart, Lowell
    Essell, James
    Owera, Rami
    Arrowsmith, Edward
    Flinn, Ian
    BLOOD, 2013, 122 (21)
  • [16] UPDATED RESULTS FOR BORTEZOMIB (BTZ)-NAIVE PATIENTS (PTS) ENROLLED IN PX-171-004, AN ONGOING OPEN-LABEL, PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ), IN RELAPSED MULTIPLE MYELOMA (MM)
    Kaufman, J. L.
    Vesole, D. H.
    Stewart, A.
    Jakubowiak, A. J.
    Jagannath, S.
    Kukreti, V.
    Mcdonagh, K. T.
    Alsina, M.
    Reu, F. J.
    Orlowski, R. Z.
    Kunkel, L.
    Le, M. H.
    Vij, R.
    Wang, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 200 - 201
  • [17] A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Kunkel, L.
    Wear, S. Sandra
    Wong, A.
    Orlowski, R. Z.
    Jagannath, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 7
  • [18] A phase ll study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma
    Siegel, D.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A.
    Lonial, S.
    Trudel, S.
    Kukreti, V
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F.
    Somlo, G.
    Zonder, J.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B.
    Rajangam, K.
    Orlowski, R.
    Jagannath, S.
    ONKOLOGIE, 2013, 36 : 38 - 39
  • [19] SAFETY AND EFFICACY UPDATE OF PX-171-004, AN OPEN-LABEL PHASE II TRIAL OF CARFILZOMIB IN RELAPSED MULTIPLE MYELOMA
    Siegel, D.
    Wang, M.
    Stewart, K.
    Jakubowiak, A.
    Jagannath, S.
    McDonagh, K.
    Kukreti, V.
    Lonial, S.
    Cruickshank, S.
    Vij, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 191 - 191
  • [20] PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update
    Vij, R.
    Wang, M.
    Orlowski, R.
    Stewart, A. K.
    Jagannath, S.
    Kukreti, V.
    Le, M. H.
    Kunkel, L.
    Siegel, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345